Spinal Cord Injury News and Research

RSS

A spinal cord injury usually begins with a sudden, traumatic blow to the spine that fractures or dislocates vertebrae. The damage begins at the moment of injury when displaced bone fragments, disc material, or ligaments bruise or tear into spinal cord tissue. Most injuries to the spinal cord don't completely sever it. Instead, an injury is more likely to cause fractures and compression of the vertebrae, which then crush and destroy the axons, extensions of nerve cells that carry signals up and down the spinal cord between the brain and the rest of the body. An injury to the spinal cord can damage a few, many, or almost all of these axons. Some injuries will allow almost complete recovery. Others will result in complete paralysis.

Study finds extensive natural recovery after spinal cord injury

A study led by researchers in the Department of Neurosciences at the University of California, San Diego School of Medicine shows unexpected and extensive natural recovery after spinal cord injury in primates. The findings, to be published November 14 in the advance online edition of Nature Neuroscience, may one day lead to the development of new treatments for patients with spinal cord injuries.

15 Nov 2010

Research may lead to new treatment options for spinal cord injuries

15 Nov 2010

TCA Cellular Therapy receives QTDP grant for adult stem cell therapies

TCA Cellular Therapy was recently awarded a Qualifying Therapeutic Discovery Program (QTDP) grant from U.S. Department of Health and Human Services. The program was highly competitive with nearly seven thousand applicants vying for funding.

14 Nov 2010

StemCyte receives two cash grants under QTDP program for biomedical research

StemCyte, Inc., one of the world's preeminent umbilical cord blood (UCB) banks and biotherapy companies, is proud to announce that the Company has been awarded two cash grants totaling $488,950 under the U.S. Internal Revenue Service's Qualifying Therapeutic Discovery Project (QTDP) program designed to support biomedical research by firms with fewer than 250 employees.

11 Nov 2010

Nutech Mediworld founder presents clinical study results of hESC therapy in patients with spinal cord injury

Dr. Geeta Shroff, founder & medical director of Nutech Mediworld, presented today the summary results of a retrospective clinical study of human embryonic stem cell (hESC) therapy in patients with chronic spinal cord injury (SCI).

11 Nov 2010

Changes in Medicare policies may hamper supply of power wheelchairs

Will power wheelchairs continue to be available to Nevada's Medicare patients following a series of federal regulatory and policy changes?

9 Nov 2010

Zynex third quarter net revenues increase 42% to $6,657,000

Zynex, Inc., a provider of pain management systems and electrotherapy products for medical patients with functional disability, announces a record number of orders and billed patients in the three months ended September 30, 2010. The Company also generated record net revenues of $6,657,000 for the three months ended September 30, 2010, which represents a 42% increase over third quarter 2009 net revenue and a 16% increase sequentially over the second quarter of 2010.

8 Nov 2010

InVivo receives $244,000 in grant funding under QTDP program

InVivo Therapeutics a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that it has been awarded $244,000 in grant funding as part of the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

3 Nov 2010

InVivo opens new development laboratory and manufacturing facility

InVivo Therapeutics Corporation, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that it has signed a lease to open its first manufacturing and development facility in Medford, Massachusetts. The company expects to use this new facility to scale up the manufacturing process for its lead product candidate, a novel biocompatible polymer scaffolding device used to treat acute open-wound SCI.

2 Nov 2010

Oxygen Biotherapeutics receives $245,000 grant under PPACA 2010

Oxygen Biotherapeutics, Inc. today announced it has received nearly $245,000 in a grant under the Patient Protection and Affordable Care Program Act of 2010 (PPACA).

2 Nov 2010

Acorda reports net income of $12.4 million for third quarter 2010

Acorda Therapeutics, Inc. today announced its financial results for the third quarter of 2010.

1 Nov 2010

StemCells initiates HuCNS-SC second clinical trial for Batten disease in children

StemCells, Inc. announced today that it has initiated a second clinical trial of its HuCNS-SC product candidate (purified human neural stem cells) in neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease), a fatal neurodegenerative disorder in children.

29 Oct 2010

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Geron Corporation today reported financial results for the three and nine months ended September 30, 2010.

29 Oct 2010

InVivo Therapeutics completes reverse merger with InVivo

InVivo Therapeutics Corporation a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced the successful completion of a reverse merger with InVivo Therapeutics Holdings Corp.

28 Oct 2010

UCI scientists receive CIRM grants to improve stem cell treatments

UC Irvine scientists will receive grants totaling $9.35 million to help create stem cell treatments for retinitis pigmentosa, Huntington's disease and traumatic brain injury.

25 Oct 2010

UCSF scientists receive grants to refine embryonic stem cell-based strategies for neurological diseases

UCSF scientists have received two grants from the California Institutefor Regenerative Medicine to refine their human embryonic stem cell-based strategies for treating neurological diseases and liver failure. The goal of the grants is for researchers to make significant strides toward the development of potential therapies within the next three years.

25 Oct 2010

Australian stem cell line offers fresh approach to diabetes cure

Australian researchers have developed the country’s first diabetes specific stem cell line, a major advance for patients suffering from the chronic disease.

21 Oct 2010

Neuralstem updates Phase I human clinical trial of spinal cord stem cells for ALS

Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.

20 Oct 2010

Acorda announces data of GGF2 preclinical studies for focal ischemic stroke

Acorda Therapeutics, Inc, today announced that data from preclinical studies show that Glial Growth Factor 2 (GGF2) promoted functional recovery following a permanent focal ischemic stroke.

19 Oct 2010

Nanotope enters agreement with Smith & Nephew to develop cartilage regeneration product

Arrowhead Research Corporation today announced that its portfolio company, Nanotope, Inc., has entered into an agreement with Smith & Nephew, Inc., a member of the Smith & Nephew plc group to develop a cartilage regeneration product for human healthcare markets using a subset of its proprietary regenerative medicine technology.

18 Oct 2010